CLEW has developed a real-time AI analytics platform using machine learning and data science to build physiological, predictive models at the individual patient level. The models have been proven successful in the ICU and are being extended to all care settings to guide clinical decision-making. The platform can be deployed at the bedside or to centralized command-and-control facilities to improve outcomes and safety, streamline patient care, and address regulatory and cost pressures. CLEW says its technology can help providers lower the cost of care and remove discharge barriers. The company closed a $20M Series B and reports total capital raised of over $20 million; the financing will be used to scale U.S. operations and commercialize the platform in the TeleICU and critical care markets. Founder and CEO Gal Salomon said the round validates the technology and highlighted strategic value from the partnership with Relyens.

Total raised

$20M

Funding rounds

1

Latest round

Series B

Latest activity

Jan 2020